Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Tocainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.44 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.44 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.44 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.44 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tocainide SCHEMBL9614374 | 1.00 | ATM (0.55) | ATMHSP90AA1PKMXIAPBIRC2 | |
| S-Tocainide SCHEMBL308742 | 0.98 | ATM (0.57) | ATMHSP90AA1PKMXIAPBIRC2 | |
| Tocainide SCHEMBL15761 | 0.98 | ATM (0.57) | ATMHSP90AA1PKMXIAPBIRC2 | |
| Tocainide SCHEMBL4338155 | 0.95 | ATM (0.54) | ATMHSP90AA1PKMXIAPBIRC2 | |
| Tocainide SCHEMBL27874301 | 0.93 | ATM (0.53) | ATMHSP90AA1PKMXIAPBIRC2 | |
| SCHEMBL11423763 | 0.85 | NLRP3 (0.52) | ATMANPEPALDH1A1MAPTMEN1 | |
| SCHEMBL11436632 | 0.84 | ATM (0.54) | ATMHSP90AA1PKMANPEPDRD2 | |
| SCHEMBL12832472 | 0.82 | ATM (0.60) | ATMHSP90AA1ANPEPDRD2HTR2A | |
| Tocainide SCHEMBL13724527 | 0.82 | SCN4A (0.65) | ATMHSP90AA1ANPEPHTR2AHTR2B | |
| SCHEMBL6356591 | 0.81 | ATM (0.58) | ATMHSP90AA1PKMANPEPDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066850-A2 | PEPTIDES AND METHODS OF TREATING DYSTROPHY-RELATED DISORDERS USING THE SAME | Bioincept LLC (US) | 2022-10-05 | — | — | EP | claimed |
| US-20150164871-A1 | Pharmaceutical Compositions for Combination Therapy | ACESION PHARMA (DK) | 2015-06-18 | — | — | US | claimed |
| EP-2861254-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | Acesion Pharma ApS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-20150045764-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE | 2015-02-12 | — | — | US | claimed |
| EP-2827884-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | Trustees Of Tufts College (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013185764-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA (DK) | 2013-12-19 | — | — | WO | claimed |
| WO-2013142119-A1 | SILK RESERVOIRS FOR DRUG DELIVERY | TRUSTEES OF TUFTS COLLEGE (US) | 2013-09-26 | — | — | WO | claimed |
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | claimed |
| EP-2432535-A2 | DRY POWDER INHALERS | 3M Innovative Properties Company (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010135340-A2 | DRY POWDER INHALERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-11-25 | — | — | WO | claimed |
| EP-1778199-A1 | COMPRESSED COMPOSITE DELIVERY SYSTEM FOR RELEASE-RATE MODULATION OF BIOACTIVES | Nutraceutix, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006022759-A1 | COMPRESSED COMPOSITE DELIVERY SYSTEM FOR RELEASE-RATE MODULATION OF BIOACTIVES | SCOLR PHARMA, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060024368-A1 | Compressed composite delivery system for release-rate modulation of bioactives | SCOLR PHARMA, INC. | 2006-02-02 | — | — | US | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124324-A1 | PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS | TUFTS COLLEGE (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735018-A2 | CENTRIFUGALLY-MOLDED ARTICLES AND METHODS | Trustees Of Tufts College (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
| US-4237068-A | Primary aminoacylanilides | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4218477-A | LONG LASTING ORAL AGENTS | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1980-08-19 | — | — | US | disclosed |
| US-4210670-A | Antithrombotic agents | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124324-A1 | PHOTOCLICK CHEMISTRY OF SILK FOR TEMPORARY UV TATTOOS | PTMS, ITK, MATK | SCN3A 2574/4885SCN4A 3619/4885SCN5A 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.